ION Breast Cancer Clinical Pathways - ION Solutions

Hycamtin (Topotecan) EP=Low; FN˃20%Topotecan 2.3mg/m 2 PO D1-5ORTopotecan 1.5mg/m 2 D1-5q 21 Day CycleORTopotecan 4mg/m 2 D1, D8, D15q 28 Day Cycle>> J Clin Oncol 17:658-667, 1999>> J Clin Oncol 24:5441-5447, 2006>> J Clin Oncol 25:2086-2092, 2007Gemzar (Gemcitabine) EP=Low; FN> J Clin Oncol 21:1550-1555, 2003>> Ann Oncol 12:557-561, 2001Hycamtin (Topotecan) Taxol (Paclitaxel) EP=Low; FN=10%-20%Topotecan 1.5mg/m2 D1-3Paclitaxel 135mg/m2 D1q 21 Day Cycle>> Oncologist: 8: 76-82, 2003Clinical Trial:Screen patient for clinical trial. Check www.clinicaltrials.gov for available trials.Best Supportive Care and/or Hospice:Consider supportive care options and Hospice when appropriate.Small Cell Lung: Extensive Disease – Third LineChemotherapy:Platinol (Cisplatin) VP-16 (Etoposide) EP=High; FN=10%-20%Cisplatin 75-80mg/m 2 D1Etoposide 80-100mg/m 2 D1-3ORCisplatin 25mg/m 2 D1-3Etoposide 100mg/m 2 D1-3q 21 Day Cycle>> J Clin Oncol 20 :4665-4672, 2002>> J Clin Oncol 12 :2022-2034, 1994>> J Clin Oncol 3:1471-1477, 1985Page 33 of 39© 2013 by ION Solutions. All rights reserved